Antigen protein, detection reagent, detection kit and application

By providing a new antigen protein that can bind to phagocytic amorphous antibodies, it solves the problems of missed detection and equipment complexity in existing amorphous disease diagnosis methods, improves the sensitivity and accuracy of detection, and is suitable for Pathogen detection of different hosts enhances the diagnosis and prevention capabilities of HGA disease.

CN118930618AInactive Publication Date: 2024-11-12INNER MONGOLIA UNIV FOR THE NATITIES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411100765.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure CN118930618A_ABST
    Figure CN118930618A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of immunology, and particularly relates to an antigen protein, a detection reagent, a detection kit and application. The amino acid sequence of the antigen protein is as shown in SEQ ID NO.3 or 4. The protein has strong antigenicity, can make up for the defect of missing detection of antibody detection of the anaplasmosis, and can improve the sensitivity of serological antibody detection, so that the anaplasmosis is effectively diagnosed clinically.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of immunology, and in particular relates to an antigen protein, a detection reagent, a detection kit and applications. Background Art

[0002] At present, the diagnostic methods of anaplasmosis include serological diagnosis, molecular biological diagnosis and pathogen diagnosis. These three diagnostic methods have their own advantages and disadvantages. Among them, the indirect immunofluorescence technique (IFA) to detect IgM\IgG against Anaplasma phagocytophilum in patient serum is currently the most widely used and most specific laboratory detection method, but this method requires the preparation of specific antigen slices, which limits its widespread use. The ELISA detection method uses the main outer membrane protein P44 protein of Anaplasma phagocytophilum as an antigen for detection. Its characteristics are easy standardization and it is also a commonly used detection method in clinical practice; but the accuracy of using a single P44 protein as an antigen is 80% to 90%, and there is a certain amount of missed detection. The molecular biological detection method has high sensitivity, simple and rapid operation, and is a commonly used diagnostic method for the acute stage of Anaplasma phagocytophilum infection; but this detection method has extremely high requirements for laboratory conditions and operating techniques, and also requires expensive instruments, which limits the wide application of this method.

[0003] According to the Centers for Disease Control and Prevention (CDC), the number of registered HGA cases increased from 348 to 5,655 cases per year between 2000 and 2019. Human granulocytic anaplasmosis (HGA) was first reported in China in 2008. Among Chinese HGA cases, symptoms of headache and muscle pain are significantly lower than those in the United States. So far, China has reported the isolation of pathogens from the blood of patients with HGA. However, the results of anaplasmosis etiology research in my country showed that its important virulence genes have obvious variation characteristics. It is particularly noteworthy that anaplasmosis presents severe clinical manifestations, with an incidence of systemic inflammatory response syndrome (SIRS) of 45.8%, an incidence of multiple organ dysfunction syndrome (MODS) of 30.1%, and a mortality rate of 26.5%.

[0004] The clinical and laboratory test results of anaplasmosis in my country are somewhat different from those of HGA reported in the United States, mainly in two aspects: one is that a slow heart rate occurred in 9 patients in China, and the other is that the antibody titer of the patient in the recovery period of the antibody test was <1:256, while 95% of the 44 HGA patients in the United States had an antibody titer ≥640. Among them, the antibody test in my country used an IgG immunofluorescence antibody kit (Focus Diagnostics, Cypress, CA, USA), and the antigen was the P44 protein of the HZ strain of Anaplasma phagocytophilum in the United States. This antigen protein is suitable for the detection of antibodies for tick-borne diseases in the United States, but the antibody detection rate for tick-borne diseases in China is low. Therefore, it is of great significance to conduct in-depth research on the pathogenic mechanism and immunogenicity of the main outer membrane protein msp2 / p44 of Anaplasma phagocytophilum in my country, and the development of the P44 antigen protein of Anaplasma phagocytophilum with strong antigenicity can be widely used in the detection of pathogens in different host animals, and at the same time can improve the accuracy of detection technology and the diagnostic accuracy of pathogens, providing important technologies and products for the diagnosis and prevention of HGA. Summary of the invention

[0005] In view of the technical problems existing in the prior art, the present invention provides an antigen protein for detecting antibodies to Anaplasmosis phagocytophilum. The protein has strong antigenicity and can make up for the defects of missed detection of antibody detection of Anaplasmosis, and can improve the sensitivity of serological antibody detection, thereby effectively diagnosing Anaplasmosis clinically.

[0006] The specific technical solutions provided by the present invention are as follows:

[0007] In a first aspect, the present invention provides an antigen protein capable of binding to an Anaplasma phagocytophilum antibody, and the amino acid sequence of the antigen protein is shown in SEQ ID NO. 3 or 4.

[0008] The second aspect of the present invention provides a use of the antigen protein in the preparation of anaplasmosis antibody drug.

[0009] The third aspect of the present invention provides the use of the antigen protein in the preparation of anaplasmosis vaccine.

[0010] Preferably, the anaplasmosis is Aphagocytic anaplasmosis.

[0011] In a fourth aspect, the present invention provides a detection reagent, which includes the antigen protein and an acceptable carrier.

[0012] The fifth aspect of the present invention provides a diagnostic kit, which includes the antigen protein and a tool for detecting anaplasmosis antibodies.

[0013] In a sixth aspect of the present invention, a pharmaceutical composition is provided, characterized in that it comprises the antigen protein. Suitable adjuvants or carriers may also be added to the pharmaceutical composition to prepare a pharmaceutical preparation that meets clinical needs. The selection of adjuvants or carriers is determined according to the specific formulation. When the pharmaceutical composition is prepared into a pharmaceutical preparation, the method used is a conventional preparation method in pharmacy.

[0014] In a seventh aspect, the present invention provides a method for producing antibodies capable of specifically binding to Anaplasma phagocytophilum, comprising using the antigen protein to immunize a non-human animal.

[0015] The invention provides an antigen protein for serological diagnosis of anaplasmosis, which improves the sensitivity of anaplasmosis detection and makes up for the defect of missed detection of antibody detection for serological diagnosis of anaplasmosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 This is a gel image of protein small-scale expression; A, AVM80370 protein, B, AVM80371 protein; M: Marker, 1: uninduced control (BL21), 2-3: IPTG induced (BL21);

[0017] Figure 2 This is a gel image of protein mass expression; A, AVM80370 protein, B, AVM80371 protein; M: Marker, 1: whole bacteria after ultrasound, 2: supernatant after ultrasound, 3: precipitate after ultrasound;

[0018] Figure 3 AVM80370 reacts positively with the patient's serum; M is a marker; R4+ is a positive control; JPS starts with a patient;

[0019] Figure 4 AVM80371 reacts positively with the patient's serum; M is a marker; R3+ and R4+ are positive controls; and those starting with ZPS are patient's serum. DETAILED DESCRIPTION

[0020] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0021] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0022] Example 1

[0023] AVM80371 gene and protein expression and purification

[0024] 1. Target gene and plasmid

[0025] The sequence of gene AVM80371 is as SEQ ID Shown in NO.1: GGAAAAGATATAGTACAATTTGCAAAGGCTGTCGAGATCAGCTCCCCGACCATCGACGGCAAGGTGTGCAGCGGAAACCACGCGAAGACCACGGCTAATAGCGGTAGCCCAAGCACGTACAGCACCAATCTGAGTTCGGGCGCATCTACGCATACCGCTCAATGTAGCGGCTTCTCCGTGA AGAGCGATACCGAAACCTTTGGTAAATTCGCCCGTACCCTGAAACCGGAGGATGGTAAGTACTGGCCGACCGGTTCTCACAGCGGCTCTGGTACAACTCCGACTCCGTATGAACAGAACTCCAACGCGAAAGCAGTTGCGAAGGACCTGGTTAAAGAGTTGACCCCGGAGGAAAAAAACCATTGTTGCG

[0026] The sequence of gene AVM80370 is as SEQ ID NO.2 shows: GGAAAAGATATAGTACAATTTGCAAAGGCTGTCGAGATCAGCCATAGCACGATTGATGACAAAATCTGCCGTACGCGTAGCGGCTCTAGCGCTAGCGGCAAATACGGCGTTTATGCAAATGAAACCACCAATAAGACCAGCAGCCGTCACAACAAGGTGGCGGTTTGTGGTGCGGAAGGTCTGGAAA ACACCGGTTCTCAGAACAGCCCGCAAGTTCTGCGTGACTTCGTGCGCGAGACTCTGAAAGGTGATGGTTCGAAGAACTGGCCAACGTCCACCGCAGCTACCGATCGCAAGCCGCAGCCGAAACCGAACGACAACGCCAACGCGGTGGCGAAGGACCTCGTTGCGCTGAACAGCGGCGAGAAAACCATTGTGGCC

[0027] The target gene fragments were double digested with EcoRI and XhoI and connected to the pET30a vector of the kanamycin resistance gene to obtain a plasmid containing the target gene AVM80371 and a plasmid containing the target gene AVM80370.

[0028] 2. Conversion

[0029] Take out the competent cells BL21 stored at -80℃ and slowly thaw them on ice. Add the competent cells to the plasmid containing the target gene and mix well. Place on ice for 30 minutes. Heat shock at 42℃ for 90 seconds, ice bath for 2 minutes, add 800μl of LB medium without resistance, and culture at 37℃ for 45 minutes. Centrifuge at 5000rpm for 3 minutes, discard most of the supernatant, keep about 100-150μl, resuspend the bacteria, select LB plates with corresponding resistance, and spread them. Dry, invert and culture overnight in a 37℃ incubator, and collect the culture liquid.

[0030] 3. Small amount expression

[0031] (1) Pick a single clone from the transformed plate and transfer it to 1.5 ml of LB liquid medium containing the corresponding resistance and culture it at 37°C and 200 rpm.

[0032] (2) Cultivate until OD 600 =0.6~0.8, IPTG (0.5mM) induction, 37℃, 200rpm, culture for 2h.

[0033] (3) Take 1 ml of the induced bacterial solution and centrifuge at 12,000 rpm for 1 min. Discard the supernatant and disperse the precipitate with 100 μl of 10 mM Tris-HCl (pH 8.0) solution (the amount of buffer added depends on the amount of bacteria). Add 2× loading buffer with an equal volume of buffer, boil at 100°C for 5 min, and detect by electrophoresis.

[0034] Depend on Figure 1 It can be seen that the picked monoclonal clone has obvious target protein expression bands.

[0035] 3. Extensive expression

[0036] (1) Add 1-2 μl of activated bacterial solution to 5 ml of LB liquid culture medium of corresponding resistance, and culture at 37°C and 200 rpm.

[0037] (2) Transfer the cultured bacterial suspension into 250 ml of the corresponding resistance LB liquid medium and culture at 37°C, 200 rpm until OD 600 =0.6~0.8, induced with IPTG (0.5mM) overnight.

[0038] (3) Harvest the cells: Centrifuge at 8000 rpm for 6 min. Discard the supernatant.

[0039] (4) Ultrasonic disruption of bacteria: The bacteria were dispersed with 20-30 ml of 10 mM Tris-HCl (pH 8.0) solution and disrupted by ultrasonic wave (500 W, 180 times, 5 s each time, 5 s interval).

[0040] (5) Determine the expression form by electrophoresis: Take 100 μl of the bacterial suspension after ultrasound, centrifuge at 12,000 rpm for 10 min, take 50 μl of the supernatant into another EP tube, remove the supernatant and blow off the precipitate with 50 μl of 10 mM Tris-HCl (pH 8.0) solution, and detect by electrophoresis to obtain a large amount of expressed antigen proteins AVM80370 and AVM80371.

[0041] Depend on Figure 2 It can be seen that the target protein is expressed in both the supernatant and the precipitate.

[0042] 4. Antigen protein purification

[0043] (1) Add 5 ml of Lysis / Wash Buffer to a nickel column tube (Ni Sepharose 6 Fast Flow, GE Healthcare) and repeat the washing twice to remove the residual protective solution.

[0044] (2) Add the above-mentioned protein expressed in large quantities into the column tube and discard the flow-through after it is dry.

[0045] (3) Add 5 ml of Lysis / Wash Buffer to the column tube for washing. Repeat this step 5 times.

[0046] (4) Add 10 ml of Elution Buffer to the column to elute the target protein and collect the effluent.

[0047] (5) Add the effluent into the column tube again, repeat step (4) twice, and collect the effluent to obtain the purified antigen protein.

[0048] The amino acid sequence of antigen protein AVM80370 is shown in SEQ ID NO.3:

[0049] GKDIVQFAKAVEISHSTIDDKICRTRSGSSASGKYGVYANETTNKTSSRHNKV

[0050] AVCGAEGLENTGSQNSPQVLRDFVRETLKGDGSKNWPTSTAATDRKPQPKP

[0051] NDNANAVAKDLVALNSGEKTIVA

[0052] The amino acid sequence of antigen protein AVM80371 is shown in SEQ ID NO.4:

[0053] GKDIVQFAKAVEISSPTIDGKVCSGNHAKTTANSGSPSTYSTNLSSGASTHTA

[0054] QCSGFSVKSDTETFGKFARTLKPEDGKYWPTGSHSGSGTTPTPYEQNSNAK

[0055] AVAKDLVKELTPEEKTIVA

[0056] Example 2

[0057] Detection of Antigenic Proteins in Antibodies to Anaplasma phagocytophilum

[0058] (1) Use a pipette to take 500 μl of protein and 500 μl of SDS-PAGE protein loading buffer 2X (denaturation) and put them into a 1.5 ml centrifuge tube and mix thoroughly. Place it in a 100°C constant temperature pot for 4 minutes to denature the protein. After the time is up, place it at room temperature to cool.

[0059] (2) 5 μl of protein marker was dropped into the first well of SDS-PAGE gel, and 10 μl of antigen protein AVM80370 and AVM80371 were expressed in the remaining wells.

[0060] (3) Connect the gel running device and run the concentrated gel at 80 V for 0.5 h and the separation gel at 100 V for 1 h for SDS-PAGE electrophoresis analysis of the recombinant protein.

[0061] (4) Transfer the membrane to PVDF membrane and connect the power supply to transfer the membrane at a current of 180 mA for 1 h.

[0062] (5) Weigh 2.5 g of skim milk powder solid on a balance and dissolve it in 50 ml of TBST. Use a rotary mixer at 40 rpm to mix for 1 h to prepare a 5% skim milk powder blocking solution.

[0063] (6) The transferred PVDF membrane was blocked with 5% skimmed milk powder in a shaking incubator at room temperature and at 80 rpm for 1 h.

[0064] (7) The membrane was cut into strips, and the rabbit polyclonal positive antibody serum (R4+, R3+) was diluted to 1:4000 and the serum of the patient bitten by tick was diluted to 1:1000 in blocking solution, and then incubated at 4°C and 100 rpm in a shaking incubator overnight.

[0065] (8) After the primary antibody incubation, the membrane was washed three times with TBST, each time for 10 min.

[0066] (9) The secondary antibody HRP-labeled Mouse Anti-Human IgG was diluted 3000 times with TBST solution and incubated at room temperature on a shaker at 100 rpm for 2 h.

[0067] (10) After the secondary antibody incubation, the membrane was washed three times with TBST, each time for 20 min.

[0068] (11) After developing the color using ECL chemiluminescent substrate for 2 min, the reaction solution was aspirated and photographed using an imaging system.

[0069] The results showed that all 8 positive sera from patients reacted with AVM80370 antigen ( Figure 3 ), all three sera reacted with AVM80371 ( Figure 4 ). This indicates that the antigen protein provided by the present invention can be used for the detection of Anaplasma phagocytophilum antibodies.

[0070] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. An antigen protein, characterized in that The antigen protein can bind to the Anaplasma phagocytophilum antibody, and its amino acid sequence is shown in SEQ ID NO. 3 or 4.

2. Use of the antigen protein according to claim 1 in the preparation of anaplasmosis antibody drug.

3. Use of the antigen protein according to claim 1 in the preparation of anaplasmosis vaccine.

4. The use according to claim 2 or 3, characterized in that: The anaplasmosis is anaplasmosis of phagocytic origin.

5. A detection reagent, characterized in that: It comprises the antigen protein according to claim 1 and an acceptable carrier.

6. A diagnostic kit, characterized in that The invention comprises the antigen protein as claimed in claim 1 and a tool for detecting anaplasmosis antibodies.

7. A pharmaceutical composition, characterized in that It comprises the antigen protein according to claim 1.

8. A method for producing an antibody capable of specifically binding to Anaplasma phagocytophilum, characterized in that: The method comprises using the antigen protein of claim 1 to immunize non-human animals.